| Project/Area Number |
22590852
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
TAZAWA Ryushi 新潟大学, 医歯学総合病院, 講師 (70301041)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKATA Koh 新潟大学, 医歯学総合病院, 教授 (80207802)
|
|---|
| Research Collaborator |
SUZUKI Takuji シンシナテイ小児病院医療センター, 研究員
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 肺胞蛋白症 / 吸入治療 / GM-CSF / 自己抗体 / バイオマーカー / 気管支肺胞洗浄 / 抗GM-CSF抗体 / 肺機能検査 / 無治療期間 / 肺活量 / GM-CSF抗体 / 気管支肺胞洗浄液 / サーファクタント / AaDO2 / 抗体産生 / クリアランス |
|---|
| Research Abstract |
Autoimmune pulmonary alveolar proteinosis (aPAP) is caused by granulocyte/macrophage-colony stimulating factor (GM-CSF) autoantibodies in the lung. Previously, we reported that GM-CSF inhalation therapy improved alveolar-arterial oxygen difference and serum biomarkers of disease severity in these patients. To figure out predictive and prognostic factors for GM-CSF inhalation therapy in aPAP, we performed retrospective analyses of BALF obtained in aPAP patients before and after GM-CSF inhalation therapy. We confirmed that GM-CSF inhalation was associated with a decrease of GM-Ab in the BALF in improved lungs, which was probably due to the restoration of clearance, and that GM-CSF inhalation decreased the concentration of total protein and SP-A in BALF, and increase interleuki-17 and cancer antigen-125 in improved lung of autoimmune pulmonary alveolar proteinosis. Furthermore, through the post-treatment, 30-month observation, we concluded that inhaled GM-CSF therapy sustained remission in more than half of cases, and baseline %VC might be a prognostic factor for disease recurrence.
|
